These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34150872)

  • 1. Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction.
    Huang P; Guo Z; Liang W; Wu Y; Zhao J; He X; Zhu W; Liu C; Dong Y; Yu Y; Dong B
    Front Cardiovasc Med; 2021; 8():681726. PubMed ID: 34150872
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction.
    Li Y; Yu Y; Wu Y; Liang W; Dong B; Xue R; Dong Y; Zhu W; Huang P
    Front Cardiovasc Med; 2021; 8():689591. PubMed ID: 34195237
    [No Abstract]   [Full Text] [Related]  

  • 3. Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology.
    Zeng S; Cai X; Zheng Y; Liu X; Ye M
    Front Cardiovasc Med; 2022; 9():966745. PubMed ID: 35990945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
    Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "Obesity Paradox" in Patients With HFpEF With or Without Comorbid Atrial Fibrillation.
    Guo L; Liu X; Yu P; Zhu W
    Front Cardiovasc Med; 2021; 8():743327. PubMed ID: 35087875
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment.
    Ye M; Choy M; Liu X; Huang P; Wu Y; Dong Y; Zhu W; Liu C
    Diabetes Res Clin Pract; 2022 Mar; 185():109805. PubMed ID: 35219761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial.
    Vaduganathan M; Claggett BL; Chatterjee NA; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Hegde SM; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):653-661. PubMed ID: 29501806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
    Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF.
    Tsujimoto T; Kajio H
    J Am Coll Cardiol; 2017 Dec; 70(22):2739-2749. PubMed ID: 29191321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
    Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.